MN-166

Drug identity checked against registry records

Also recorded as ibudilast

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898MediciNovaPhase 2, Phase 3Active not recruiting2027-04Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.